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The NHz-terminal 1Zresidue peptide of cuz-plasmin inhibitor, Asn-Gln-Glu-Gln-Val-Ser-Pro-Leu- 
Thr-Gly-Leu-Lys-NHz. AcOH, was found to be a good substrate for plasma transglutaminase 
(activated blood coagulation factor XIII) and rapidly incorporated into fibrin by the enzyme. A high 
concentration of the peptide inhibited the enzyme-mediated cross-linking of cY2-plasmin i hibitor to fibrin 
probably by competing with the inhibitor for the same site of fibrin a-chain. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
We have shown that az-plasmin inhibitor (cuzPI) 
is cross-linked to fibrin by plasma trans- 
glutaminase, activated coagulation factor XIII 
(XIIIa), when blood coagulation takes place [l-4]. 
The cross-linking of w2PI renders fibrin clot more 
resistant o fibrinolytic process that occurs subse- 
quently to fibrin formation and is caused by fibrin- 
associated plasminogen activation [5]. a2PI serves 
only as a glutamine substrate for XIIIa in the 
cross-linking reaction [4], and the cross-linking oc- 
curs between lysine residues of fibrin a-chains and 
a glutamine residue of QPI molecule that is the se- 
cond residue from the NHz-terminal [4]. 
2.1. Proteins 
Here, the synthesized peptide which has the 
same amino acid sequence as that of the 
NHz-terminal part of azP1 is shown to be cross- 
linked to fibrin by XIIIa and thereby competetive- 
ly inhibits the cross-linking of CVZPI to fibrin. 
LYZPI, fibrinogen and blood coagulation factor 
XIII were purified from human plasma as in [6-81. 
Contaminating plasminogen and fibronectin were 
removed from the fibrinogen preparation using 
lysine-Sepharose [9] and gelatin-Sepharose [lo], 
respectively. The factor XIII present as a contami- 
nant in the fibrinogen preparation (300 mg pro- 
tein/100 ml) was 0.2 U/ml as assayed by antibody 
neutralization method [ 1 l] using the clotting factor 
XIII-test kit supplied by Behringwerke AG (Mar- 
burg). One unit of factor XIII is defined as the 
amount of factor XIII present in 1 ml normal 
pooled standard plasma. Purified thrombin was 
prepared from a bovine thrombin preparation 
(Mochida Pharmaceuticals, Tokyo) as in [12]. 
2.2. NH2-terminal peptide of CVZPI 
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The NHz-terminal 12-residue peptide of (u2PI 
(N-peptide), Asn-Gln-Glu-Gln-Val-Ser-Pro- 
Leu-Thr-Gly-Leu-Lys-NH2 - AcOH [I 31, was 
synthesized by Protein Research Foundation 
(Minoo, Osaka). 
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2.3. Radioiodination of proteins and peptide 
Purified proteins &PI and fibrinogen) were 
radioiodinated by the solid-state lactoperoxidase 
method [ 141 using lactoperoxidase (Calbiochem- 
Behring-American Hoechst Corp., San Diego 
CA) and Na”‘I (17 Ci/mg) (New England 
Nuclear, Boston MA). The labelled (r2PI and 
fibrinogen preparations had spec. act. 5.2 x 10’ 
cpm/pg and 1.2 x lo5 cpm/pg, respectively. N- 
peptide was radioiodinated as in [15] using N- 
succinimidyl 3-(4-hydroxy, 5-[1251]iodophenyl) 
propionate (1.86 Ci/pmol) (Radiochemical Centre, 
Amersham). Free unconjugated radiolabelled 
compounds were removed by gel filtration using 
Sephadex G-10. The radioiodinated N-peptide had 
spec. act. 3.9 x lo5 cpm/pg. 
2.4. Measurement of the cross-linking to fibrin 
Fibrinogen, N-peptide and/or (u2PI were mixed, 
clotted and cross-linked at 37°C by thrombin, fac- 
tor XIII, CaCl2 in Tris-buffered saline (0.05 M 
Tris-HC1/0.15 M NaCl, pH 7.4). Radioactively 
labelled N-peptide, a2PI or fibrinogen was used 
for estimating the extent of cross-linking of each 
respective component. After allowing the cross- 
linking reaction to proceed for various lengths of 
time, the extent of cross-linking was examined as 
in [2,4]. 
3. RESULTS AND DISCUSSION 
N-peptide was rapidly cross-linked to fibrin 
when the mixtures of N-peptide, factor XIII and 
fibrinogen were clotted with thrombin and calcium 
ions (fig. 1). This supports the finding that Gln-2 
is the site where CVZPI is cross-linked to fibrin [4]. 
With 1 unit of factor XIII/ml, the cross-linking of 
N-peptide was completed within 5 min. This reac- 
tion rate is similar to that of cu2PI which is the most 
efficient substrate for XIIIa among known XIIIa 
substrate plasma proteins [ 161, Although the reac- 
tion rate was dependent on the concentration of 
factor XIII, the maximum level of cross-linking 
achieved was independent of factor XIII and deter- 
mined by the concentrations of fibrinogen and N- 
peptide (fig. 1,2). When N-peptide concentration 
was increased and became a large molar excess 
over fibrinogen, the increase of the cross-linking 
deviated from linearity and fell off to reach a 
plateau (fig. 3). At the maximum plateau level, 
Incubation Time (mid 
Fig. 1. Time-course of the cross-linking reaction of N- 
peptide to fibrin. Radioiodinated N-peptide (1 ,uM), 
fibrinogen (300 mg/lOO ml), factor XIII, and thrombin 
(0.33 U/ml) were mixed and incubated at 37’C. Factor 
XIII was 0.2 U/ml (0) and 1 U/ml (0). The amount of 
N-peptide cross-linked tothe formed fibrin after various 
times of incubation was determined. 
Fibrin (mg/ml) 
Fig. 2. The relationship between the concentrations of 
fibrin and the amounts of cross-linked N-peptide. The 
experimental conditions were the same as those in fig. 1, 
except for variation of fibrinogen concentration and a 
fixed length of incubation time (30 min). Factor XIII 
was 1 U/ml. 
- 17 molecules of N-peptide were bound to each LY- 
chain of fibrin. These modes of reaction are the 
same as those observed in the azPI-fibrin(ogen) 
cross-linking reaction [2,3] and may be similarly 
explained by an equilibrium of the reaction [3]. 
The cross-linking of a2PI to fibrin was decreased 
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Fig. 3. Increase of cross-linked N-peptide and decrease 
of cross-linked LY~PI with increasing concentrations of 
N-peptide. Fibrinogen (300 mg/lOO ml), azP1 (1 PM), 
various concentrations of N-peptide, CaC12 (5 mM) and 
thrombin (0.33 U/ml) were mixed and incubated at 
37°C. The amounts of the peptide (o---o) or (r2PI (0) 
cross-linked to the formed fibrin after 30 min incubation 
were determined using radiolabelled N-peptide or a2P1, 
respectively. 
by the presence of N-peptide. The decrease was in 
inverse relationship to the increase of cross-linking 
of N-peptide (fig.3). However, a very high concen- 
tration of the peptide was required to inhibit a2PI 
cross-linking. The 50% reduction of (YzPI cross- 
linking in the presence of 1 ,uM LYZPI was achieved 
by an addition of -350 PM of N-peptide (fig.3). At 
this level (50%) of inhibition of CQPI cross-linking, 
the molar ratio of cross-linked N-peptide to cross- 
linked CQPI was estimated to be about 1000: 1. 
These findings suggest that LY~PI is cross-linked 
very efficiently to a specific site of fibrin a-chain, 
and N-peptide can not compete efficiently for this 
site with a2PI. Probably some structure of (YzPI 
molecule other than the NHz-terminal region is re- 
quired for the efficient interaction of XIIIa with 
CVZPI of factor XIII-CQPI intermediate complex [3] 
with its complementary site (lysine residue) of 
fibrin. A contribution to specificity of amino acid 
residues located some distance from the substrate 
glutamine was indicated in the study of synthetic 
glutamine substrates for XIIIa [17]. 
Cross-linked polymerization of fibrin a-chains 
was also decreased when the concentration of N- 
peptide was > 1 mM. Cross-linked dimerization of 
y-chains was not affected by N-peptide. 
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